We have recently published, in Medicinal Research Reviews, a paper about survivin protein in cancer. In this review, therapeutic options targeting survivin for cancer treatment are analyzed. Direct survivin inhibitors and their current development status are explored. Moreover, the major signaling pathways implicated in survivin regulation are described and different therapeutic approaches involving survivin indirect inhibition are evaluated. Finally, promising novel inhibitors under preclinical or clinical evaluation as well as challenges of developing survivin inhibitors as a new therapy for cancer treatment are discussed.
